202197-31-7

Usage

Uses

Used in Pharmaceutical Development:
5-Amino-1-(3-fluorobenzyl)indazole is used as a pharmaceutical intermediate for the synthesis of various drug candidates. Its unique structure and functional groups enable it to interact with biological targets, making it a valuable component in the development of new therapeutic agents.
Used in Biochemical Research:
5-Amino-1-(3-fluorobenzyl)indazole is used as a biochemical tool in studying various biological processes. Its specific interactions with proteins, enzymes, and other biomolecules can provide insights into the mechanisms of action and potential applications in drug discovery.
Used in Drug Discovery:
5-Amino-1-(3-fluorobenzyl)indazole is used as a lead compound in drug discovery, where its structure can be further optimized to enhance its therapeutic properties. Its potential as a therapeutic agent is currently under investigation, with ongoing research focusing on its synthesis, properties, and biological activity.
Used in Medicinal Chemistry:
5-Amino-1-(3-fluorobenzyl)indazole is used in medicinal chemistry for the design and synthesis of novel compounds with potential therapeutic applications. Its unique structural features and functional groups make it a promising candidate for the development of new drugs targeting various diseases and conditions.
Used in Chemical Synthesis:
5-Amino-1-(3-fluorobenzyl)indazole is used as a key building block in the synthesis of more complex organic compounds. Its versatile structure allows for further functionalization and modification, enabling the creation of a wide range of chemical entities with diverse applications in various fields.

InChI:InChI=1/C14H12FN3/c15-12-3-1-2-10(6-12)9-18-14-5-4-13(16)7-11(14)8-17-18/h1-8H,9,16H2

Upstream product

• 456-42-8 m-fluorobenzyl chloride 
• 5401-94-5 5-nitroindazole 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 884874-01-5 2-(3-fluorobenzyl)-5-nitro-2H-indazole 
• 529508-58-5 1-(3-fluorobenzyl)-5-nitro-1H-carbazole 

Downstream Products

• 697299-99-3 [1-(3-fluoro-benzyl)-1H-indazol-5-yl]-(6-iodo-quinazolin-4-yl)-amine hydrochloride 
• 529509-71-5 4-{4-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy}-piperidine-1-carboxylic acid tert-butyl ester 
• 914308-84-2 4-chloro-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidine-5-carbonitrile 
• 897025-61-5 N⁴-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxyquinazoline-4,6-diamine 
• 1353644-76-4 C₃₀H₂₃FN₆O₃ 
• 1353644-68-4 (3aR,6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3 ,4-b]pyrrole-5(1 H)-carboxamide 
• 1353644-75-3 N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxy-6-nitroquinazolin-4-amine 
• 1351125-34-2 C₂₇H₂₈FN₃O₆ 
• 1351125-05-7 C₂₁H₁₅FIN₃O₂ 
• 1351125-19-3 C₂₆H₁₈FN₃O₄ 
• 1351125-39-7 C₂₉H₂₇FN₄O₅S 
• 1021942-18-6 4-amino-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidine-5-carbaldehyde 
• 878018-69-0 N-[1-(3-fluorobenzyl)-1H-indazol-5-yl]amino-5,8-dihydro-6H-spiro[1-benzothieno[2,3-d]pyrimidine-7,2'-[1,3]dioxolan]-4-amine hydrochloride 
• 744194-19-2 5-fluoro-N-[1-(3-fluorobenzyl)-1H-indazol-5-yl]quinazolin-4-amine 

Relevant academic research and scientific papers

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

QUINAZOLINE COMPOUNDS

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compound can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

QUINAZOLINE COMPOUNDS

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

Synthesis and cytotoxic activity of 2,5-disubstituted pyrimido[5,4-c] quinoline derivatives

A series of 2,5-disubstituted pyrimido[5,4-c]quinoline derivatives were synthesized and their cytotoxic activity against H460, HT-29 and MDA-MB-231 cell lines was evaluated in vitro. It was found that most of the tested compounds especially compound 17, s

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof

This invention relates to compounds of Formula (I), wherein the variables are as disclosed in the specification, to pharmaceutical compositions containing them, to methods of making the compounds and pharmaceutical compositions, and to methods of using th

SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

Aniline 'headgroups' were synthesized and incorporated into an alkynyl thienopyrimidine series of EGFR and ErbB-2 inhibitors. Potent inhibition of enzyme activity and cellular proliferation was observed. In certain instances, protein binding was reduced a

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epide

Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino] pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectiv

THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS

The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.